title: A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma.
abstract: OBJECTIVE
  To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC).
  
  
  METHODS
  Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks.
  
  
  RESULTS
  Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% CI: 2.6-3.4), the median survival 10.6 months (95% CI: 8.7-12.4), with no difference between pre-treated patients and others. Treatment was well tolerated.
  
  
  CONCLUSIONS
  The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma.
authors.affiliation: Centre René Gauducheau, Nantes, France. j-bennouna@nantes.fnclcc.fr
authors.forename: J
authors.initials: J
authors.lastname: Bennouna
authors.forename: R
authors.initials: R
authors.lastname: Delva
authors.forename: F
authors.initials: F
authors.lastname: Gomez
authors.forename: T
authors.initials: T
authors.lastname: Lesimple
authors.forename: L
authors.initials: L
authors.lastname: Geoffrois
authors.forename: C
authors.initials: C
authors.lastname: Linassier
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: J Y
authors.initials: JY
authors.lastname: Douillard
authors.forename: S
authors.initials: S
authors.lastname: Négrier
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002955:Leucovorin / Q000627:therapeutic use*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009944:Organoplatinum Compounds; D011379:Prognosis; D012449:Safety; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil